Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Downgraded by Wall Street Zen to Buy

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

A number of other equities research analysts also recently issued reports on the stock. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wells Fargo & Company upped their target price on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 9th. Finally, Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $33.49 on Friday. The company has a market capitalization of $2.48 billion, a PE ratio of 837.46 and a beta of 0.20. The stock’s fifty day moving average is $30.31 and its 200-day moving average is $26.06. Kiniksa Pharmaceuticals International has a one year low of $17.82 and a one year high of $34.55.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, COO Eben Tessari sold 138,614 shares of the company’s stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $33.20, for a total transaction of $4,601,984.80. Following the completion of the transaction, the chief operating officer directly owned 49,915 shares in the company, valued at $1,657,178. This represents a 73.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Ross Moat sold 27,594 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total transaction of $800,777.88. Following the completion of the sale, the insider directly owned 9,415 shares of the company’s stock, valued at approximately $273,223.30. This trade represents a 74.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 593,416 shares of company stock valued at $18,924,806. 53.48% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $301,000. GAMMA Investing LLC raised its holdings in Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after acquiring an additional 568 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Kiniksa Pharmaceuticals International by 177.1% in the 1st quarter. Deutsche Bank AG now owns 394,522 shares of the company’s stock worth $8,762,000 after acquiring an additional 252,125 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $1,184,000. Finally, Nuveen Asset Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 7.3% during the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company’s stock worth $15,737,000 after purchasing an additional 54,361 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.